Advertisement


William Gradishar, MD, on Breast Cancer Guideline Updates

2016 NCCN Annual Conference (1)

Advertisement

William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.



Related Videos

Breast Cancer

Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.

Lung Cancer

Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection

Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.

Palliative Care

Toby C. Campbell, MD, on Palliative Care: Patient and Provider Perspectives

Toby C. Campbell, MD, of the University of Wisconsin Carbone Cancer Center, discusses palliative care, hospice care, and best supportive care practices, as well as the challenges of symptom management and end-of-life issues.

Gastroesophageal Cancer

Jaffer Ajani, MD, on Metastatic Gastroesophageal Cancers: Expert Perspective

Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.

Leukemia

Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents

Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.

Advertisement

Advertisement




Advertisement